Cellular Immunotherapy lab

• Mechanisms of resistance to CAR T-cell immunotherapy
• Novel targets for lymphoma, leukemia, and autoimmune diseases
• Gene-editing strategies (CRISPR/base editing) to improve efficacy and safety
• Metabolic and microenvironmental regulation of T-cell therapies
• Translation of engineered T-cell products to phase I clinical trials

Dr. Ruella's work has been recognized with numerous national and international awards, including:

• SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship
• AACR–BMS Oncology Fellowship
• ASH Scholar Award
• NIH K99/R00 and R01/R37 Awards
• LLS Translational Research Program Awards
• American Society for Clinical Investigation (ASCI) membership
• Penn Inventor of the Year (2024)

Dr. Ruella is the scientific founder of viTToria Biotherapeutics, a clinical-stage company developing next-generation T-cell therapies. He serves as an advisor or consultant to several biotech and pharmaceutical companies in the immuno-oncology field. He is also an inventor on multiple U.S. and international patents covering novel CAR T-cell designs, gene-edited cellular therapies, and metabolic reprogramming strategies, several of which have been licensed for translational and commercial development.

• LinkedIn: https://linkedin.com/in/marco-ruella-a3881542
• X: @MarcoRuella | @RuellaLab
• ORCID: 0000-0003-4301-5811
• MyNCBI Publications: https://www.ncbi.nlm.nih.gov/myncbi/marco.ruella.1/bibliography/public/
• Google Scholar: https://scholar.google.com/citations?user=khHtvg8AAAAJ&hl=en